Delta Financial Advisors LLC Purchases 4,830 Shares of AbbVie Inc. $ABBV

Delta Financial Advisors LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 225.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 6,971 shares of the company’s stock after purchasing an additional 4,830 shares during the period. Delta Financial Advisors LLC’s holdings in AbbVie were worth $1,614,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ABBV. Vanguard Group Inc. lifted its stake in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the period. Geode Capital Management LLC boosted its position in AbbVie by 2.4% during the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after acquiring an additional 924,761 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock valued at $4,970,848,000 after acquiring an additional 1,517,222 shares in the last quarter. Norges Bank bought a new position in shares of AbbVie in the second quarter valued at $4,288,200,000. Finally, Raymond James Financial Inc. increased its stake in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on ABBV. Morgan Stanley upped their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Wall Street Zen cut shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday. Bank of America increased their price target on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group reaffirmed a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $248.11.

AbbVie Stock Up 0.5%

ABBV stock opened at $219.21 on Friday. The business has a 50 day moving average of $225.60 and a 200-day moving average of $217.22. The firm has a market cap of $387.42 billion, a PE ratio of 166.07, a P/E/G ratio of 0.90 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. During the same quarter in the previous year, the firm posted $3.00 earnings per share. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is currently 524.24%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.